高危型人乳头瘤病毒（human papillomavirus，HPV）感染是宫颈癌的主要诱因。HPV主要衣壳蛋白L1在外源表达系统中可以自我组装成与天然病毒类似的病毒样颗粒(virus-like particle，VLP)，后者可以在动物和人体中诱导高滴度中和性抗体，因此，HPV L1 VLP成为理想的预防性疫苗候选物。目前已建立了多种实验方法来评价疫苗的免疫原性，其中竞争性Luminex 免疫试验将成为未来HPV疫苗免疫原性检测的有效方法。

High-risk type human papillomaviruses (HPVs) are respensible for cervical cancer cases. The major capsid protein L1 can be expressed in a heterogenous expression system and self-assemble into virus-like particles (VLPs), which elicit high-titer neutralizing antibodies in animal models and human. Therefore, HPV L1 VLP becomes a perfect candidate of prophylactic vaccines. Various assays have been developed to evaluate immunogenicity of the vaccine. Competitive Luminex immunoassay may be a potential serological assay in the future.